Open Access Open Access  Restricted Access Subscription or Fee Access

Opioid-induced constipation in mixed chronic pain patients: Prevalence and predictors analysis

Boaz Gedaliahu Samolsky Dekel, MD, PhD, Maria Cristina Sorella, MD, Alessio Vasarri, MD, Alberto Gori, MD, Rita Maria Melotti, MD

Abstract


Objectives: Assessment of opioid-induced constipation (OIC) prevalence and relationship with demographic, clinical, and drug predictors in our daily practice.

Design: Observational and retrospective study.

Setting: Chronic pain (CP) center of Bologna’s Teaching Hospital, Italy.

Subjects: Mixed consecutive CP opioid-user outpatients (n = 128).

Main outcome measure(s): OIC was assessed with the Bowel Function Index (BFI) in three consecutive visits. Absolute difference and Student’s t-test were used to compare BFI scores. Predictors (opioid compound and type, morphine-equivalent daily-dose [MEDD], and laxatives) were retrieved from the patients’ charts. BFI and predictors relationships were checked by multinomial logistic regression (MLR); independent predictors of BFI scores were assessed with χ 2 analysis.

Results: Of the 384 evaluations, 85 percent were on strong opioids with a MEDD range of 11-50 mg per day in the majority (60 percent) and 64 percent showed moderate constipation; 42 percent did not use laxatives while 24 percent used macrogol with significant decrease in the BFI. MLR showed that oxycodone was associated with a risk for moderate constipation. Lactulose and glycerin suppositories were associated with severe constipation. Non-opioid users and cancer patients were associated with normal bowel function and severe constipation, respectively.

Conclusions: OIC was found in almost all evaluations of weak or strong opioid users (97 percent); moderate to severe OIC was found in 72 percent of the evaluations. Cancer patients were associated with severe constipation. Macrogol was superior to other laxatives. In our experience, macrogol relieved constipation in those on the combination of oxycodone and naloxone and in those on fentanyl patches. Lactulose and glycerol suppositories were associated with severe constipation.


Keywords


opioid-induced constipation, prevalence, Bowel Function Index, opioid, morphine-equivalent daily-dose, laxatives, macrogol, peripherally acting μ-opioid receptor, antagonists

Full Text:

PDF

References


Trescot AM, Glaser SE, Hansen H, et al.: Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician. 2008; 11 (2 suppl): S181-S200.

Dart RC, Severtson SG, Bucher-Bartelson B: Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015; 372 (3): 241-248.

McNicol E, et al: Management of opioid side effects in cancer- related and chronic noncancer pain: A systematic review. J Pain. 2003; 4 (5): 231-256.

Klepstad P, Borchgrevink PC, Kaasa S: Effects on cancer patients’ health-related quality of life after the start of morphine therapy. J Pain Symptom Manage. 2000; 20 (1): 19-26.

Pappagallo M: Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001; 182 (5): S11-S18.

Panchal SJ, Müller-Schwefe P, Wurzelmann JI: Opioid-induced bowel dysfunction: Prevalence, pathophysiology and burden. Int J Clin Pract. 2007; 61 (7): 1181-1187.

Camilleri M, Drossman DA, Becker G, et al.: Emerging treatments in neurogastroenterology: A multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014; 26 (10): 1386-1395.

Gaertner J, Siemens W, Camilleri M, et al.: Definitions and outcome measures of clinical trials regarding opioid-induced constipation: A systematic review. J Clin Gastroenterol. 2015; 49 (1): 9-16.

Keefer L, Drossman DA, Guthrie E, et al.: Centrally mediated disorders of gastrointestinal pain. Gastroenterology. 2016; 150 (6): 1408-1419.

Camilleri M: Opioid-induced constipation: Challenges and therapeutic opportunities. Am J Gastroenterol. 2011; 106 (5): 835-842.

Rachinger-Adam B, Conzen P, Azad SC: Pharmacology of peripheral opioid receptors. Curr Opin Anaesthesiol. 2011; 24 (4): 408-413.

Pergolizzi JV Jr, Raffa RB, Pappagallo M, et al.: Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. Patient Prefer Adherence. 2017; 11: 107-119.

Müller-Lissner S, Bassotti G, Coffin B, et al.: Opioid-induced constipation and bowel dysfunction: A clinical guideline. Pain Med. 2017; 18 (10): 1837-1863.

Rentz AM, Yu R, Müller-Lissner S, et al.: Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009; 12 (4): 371-383.

Abramowitz L, Béziaud N, Caussé C, et al.: Further validation of the psychometric properties of the Bowel Function Index for evaluating opioid-induced constipation (OIC). J Med Econ. 2013; 16 (12): 1434-1441.

World Health Organization, Regional Office for Europe: Body mass index – BMI [Online]. Available at http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/ahealthy-lifestyle/body-mass-index-bmi. Accessed October 31, 2018.

Treillet E, Laurent S, Hadjiat Y: Practical management of opioid rotation and equianalgesia. J Pain Res. 2018; 11: 2587-2601.

Gallegos-Orozco JF, Foxx-Orenstein AE, Sterler SM, et al.: Chronic constipation in the elderly. Am J Gastroenterol. 2012; 107 (1): 18-25; quiz 26.

Vazquez Roque M, Bouras EP: Epidemiology and management of chronic constipation in elderly patients. Clin Interv Aging. 2015; 10: 919-930.

Abramowitz L, Béziaud N, Labreze L, et al.: Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: A cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med Econ. 2013; 16 (12): 1423-1433.

Olesen AE, Drewes AM: Validated tools for evaluating opioid- induced bowel dysfunction. Adv Ther. 2011; 28 (4): 279-294.

Camilleri M, Rothman M, Ho KF, et al.: Validation of a bowel function diary for assessing opioid-induced constipation. Am J Gastroenterol. 2011; 106 (3): 497-506.

Argoff CE, Brennan MJ, Camilleri M, et al.: Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. 2015; 16 (12): 2324-2337.

Cowan DT, Wilson-Barnett J, Griffiths P, et al.: A survey of chronic noncancer pain patients prescribed opioid analgesics. Pain Med. 2003; 4 (4): 340-351.

Bell TJ, Panchal SJ, Miaskowski C, et al.: The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a US and European Patient Survey (PROBE 1). Pain Med. 2009; 10 (1): 35-42.

Ducrotté P, Milce J, Soufflet C, et al.: Prevalence and clinical features of opioid-induced constipation in the general population: A French study of 15,000 individuals. United European Gastroenterol J. 2017; 5 (4): 588-600.

Staats PS, Markowitz J, Schein J: Incidence of constipation associated with long-acting opioid therapy: A comparative study. South Med J. 2004; 97 (2): 129-134.

Kress HG, Von der Laage D, Hoerauf KH, et al.: A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom Manage. 2008; 36 (3): 268-279.

Melilli G, Samolsky Dekel BG, Frenquelli C, et al.: Transdermal opioids for cancer pain control in patients with renal impairment. J Opioid Manag. 2014; 10 (2): 85-93.

Devulder J, Richarz U, Nataraja SH: Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin. 2005; 21 (10): 1555-1568.

Pottegård A, Knudsen TB, van Heesch K, et al.: Information on risk of constipation for Danish users of opioids, and their laxative use. Int J Clin Pharm. 2014; 36 (2): 291-294.

Fritz E, Hammer HF, Lipp RW, et al.: Effects of lactulose and polyethylene glycol on colonic transit. Aliment Pharmacol Ther. 2005; 21 (3): 259-268.

DiPalma JA, Cleveland MVB, McGowan J, et al.: A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007; 102 (7): 1436-1441.

Chaussade S, Minic M: Comparison of efficacy and safety of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation. Aliment Pharmacol Ther. 2003; 17 (1): 165-172.

Cryer B, Katz S, Vallejo R, et al.: A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 2014; 15 (11): 1825-1834.

Wirz S, Nadstawek J, Elsen C, et al.: Laxative management in ambulatory cancer patients on opioid therapy: A prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose. Eur J Cancer Care (Engl). 2012; 21 (1): 131-140.

Attar A, Lemann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut. 1999; 44 (2): 226-230.

Basilisco G, Marino B, Passerini L, et al.: Abdominal distension after colonic lactulose fermentation recorded by a new extensometer. Neurogastroenterol Motil. 2003; 15 (4): 427-433.

Ahmedzai SH, Boland J: Constipation in people prescribed opioids. BMJ Clin Evid. 2010; 2010: pii: 2407.

Fudin J, Pratt Cleary J, Schatman ME: The MEDD myth: The impact of pseudoscience on pain research and prescribing-guideline development. J Pain Res. 2016; 9: 153-156.




DOI: https://doi.org/10.5055/jom.2019.0527

Refbacks

  • There are currently no refbacks.